Objectives: To assess and compare the current trends in bacteraemia and antimicrobial resistance and analyse the impact of ciprofloxacin prescribing on Gram-negative bacterial resistance in haematology and oncology patients.
Introduction
Severe infections remain a major complication for cancer patients, leading frequently to hospitalization and increased mortality. 1, 2 Myelosuppressive cytotoxic chemotherapy and some malignancies themselves lead to immunosuppression and an increased risk of infection. In the USA it has been estimated that the incidence of sepsis is as high as 16.4 cases/ 1000 cancer patients/year, with an in-hospital mortality of 38%. 2 Appropriate prophylactic and empirical antimicrobial chemotherapy is therefore important in order to reduce morbidity and mortality in these susceptible patients.
Antimicrobial prescribing depends greatly on the local prevalence of pathogens causing infection and their antibiotic susceptibility, which may change over time. In the past, Gram-negative bacteria, especially Escherichia coli, Pseudomonas aeruginosa and Klebsiella spp., were globally dominant until the 1990s, whereas thereafter Gram-positive bacteria became predominant. 3 This shift has been attributed to the use of more intravascular devices and also to potent cytotoxic drug regimens that predispose patients to prolonged neutropenia and severe mucositis. 4 Antibiotic resistance patterns have also changed in recent decades, probably due to the selective pressure imposed by frequently used antibiotics. 5 Intrinsically more resistant Stenotrophomonas multophilia and Acinetobacter spp. were rare organisms prior to the 1990s, but are now more common. 6 The introduction of routine fluoroquinolone prophylaxis for neutropenic patients since the early 1990s has been accompanied by a significant fall in the number of febrile neutropenic episodes, but at the same time fluoroquinolone resistance has emerged across Gram-positive and Gram-negative bacteria. 7, 8 Regular surveillance and review of the incidence of bacterial causes of sepsis and antimicrobial susceptibility is therefore important in order to devise and implement effective antibiotic policies.
We therefore conducted a longitudinal 14 year surveillance study at a large regional UK cancer centre to determine recent trends in bacteraemia and antimicrobial resistance in haematology and oncology patients, reflecting routine clinical practice. We also analysed the impact of ciprofloxacin consumption on antimicrobial resistance of bacteraemia isolates among cancer patients.
Methods

Data collection and case definition
The study was undertaken at the Norfolk and Norwich University Foundation Hospital Trust (NNUH), UK. The hospital is a 1000 bed teaching hospital with a large regional cancer centre dealing on average with 3060 haematology and 8453 oncology admissions/year. Surveillance data on significant bacteraemia isolates and their resistance were obtained from a prospective database collection of adult patients (≥18 years old) established as part of the routine diagnostic service at the NNUH Microbiology Department for the period 1997-2010.
Information extracted from the database included episodes of significant bacteraemia, the types of microorganisms isolated and their antimicrobial susceptibility pattern to commonly used antibiotics (ciprofloxacin, ceftazidime, gentamicin, piperacillin/tazobactam and meropenem). The data were collected by one of the investigators and cross-checked by another to ensure consistency of case definition and data acquisition.
A significant bacteraemia was defined as a positive blood culture with an organism thought to be causing the clinical infection in conjunction with raised inflammatory markers and clinical signs and symptoms of infection at the time of presentation. Multiple isolates of the same organism cultured from blood within 14 days were regarded as a single bacteraemia episode.
Laboratory investigations
Blood cultures were carried out using the BACT/Alert 3D system (bioMér-ieux Inc.) throughout the study period. The BACT/Alert Classic was used for blood cultures until 2004 and was upgraded to the BACT/Alert 3D thereafter. The isolates were cultured according to standard operating procedures of the HPA, UK, and identified based on colony appearance/ biochemical characteristics (API system, bioMérieux Inc.) and from 2008 also by the Vitek automated system (bioMérieux Vitek Inc.). 9 The antibiotic sensitivities of significant isolates were determined by disc diffusion or MIC methods. 10 The isolates were classified either as resistant or susceptible based on zone sizes or breakpoints according to respective guidelines. 10 
Antibiotic policy and consumption
First-line empirical treatment of febrile episodes or sepsis in cancer patients was ceftazidime (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) or piperacillin/tazobactam (2004-10) in combination with gentamicin. The second-line antibiotic was meropenem. Oral ciprofloxacin prophylaxis was prescribed routinely for neutropenic haematology patients. Fluconazole prophylaxis was used routinely for neutropenic patients in haematology.
Ciprofloxacin usage was calculated using a modification of the WHO definition of defined daily dose (DDD) of ciprofloxacin as 500 mg/unit and this was calculated/10 admissions (DDDs/10 admissions).
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Information on the total number of admissions/year and the amount of ciprofloxacin consumed for haematology and oncology patients for each year was obtained from the NNUH hospital statistics and pharmacy department.
Statistical analysis
Statistical analysis was done with STATA v11. All regression analyses were done using Poisson regression with the count of the outcome as the dependent variable and the relevant denominator being the exposure variable. Prior to regression analysis, all series were first tested for autocorrelation using Pearson and Spearman correlation coefficients between the dependent variable as an incidence and its lagged value.
Results
The surveillance of bloodstream infections among the cancer population revealed a total of 914 significant bacteraemia episodes over a 14 year period with 473 episodes attributed to patients with haematological malignancies and 441 episodes in patients with solid cancers. This equates to an overall incidence of bacteraemia for all cancer patients of 5.5/1000 admissions, whereas the individual incidence for haematology was 3-fold higher compared with oncology patients (10.9/1000 admissions versus 3.6/1000 admissions, respectively) [incidence rate ratio (IRR) 3.0, 95% CI 2.6 -3.4, P,0.0001]. There was a fluctuation in bacteraemia rate over the 14 years for both specialties. For haematology patients there was a significant downward trend in bacteraemia episodes (IRR/year 0.97, 95% CI 0.94-0.99) (Pearson's goodness of fit x 2 ¼ 13.82, df ¼ 12, P ¼ 0.312, model accepted), but not among patients with solid tumours (IRR/year 1.01, 95% CI 0.99 -1.04) (Figures 1 and 2 ). As seen in Figures 1 and 2 , there was no specific trend in the incidence of Gram-negative or -positive bacteraemia over the 14 year time period.
The total number of pathogens isolated from blood cultures was 488 for haematology and 461 for oncology. The distribution of Gram-positive (62%, n¼ 302 haematology, 56%, n¼ 258 oncology) and Gram-negative bacteria (33.4%, n ¼163 haematology, 41%, n¼ 189 oncology) differed between the two groups of patients (x 2 ¼ 6.80, df ¼ 2, P ¼0.03). In the group of Gram-positive pathogens causing bacteraemia, coagulase-negative staphylococci were the predominant isolates in both patient groups ( Table 1 ). The overall incidence of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia was 0.16/1000 cancer patient admissions. Although haematology patients showed a higher incidence of S. aureus bacteraemia compared with oncology patients (0.85, 95% CI 0.62-1.17 versus 0.36, 95% CI, 0.26-0.49, respectively) ( Table 1 and did not show any marked differences between the cancer groups except for Enterococcus, which had a higher bacteraemia rate in the haematology group (0.46, 95% CI 0.28-0.71) compared with the oncology group (0.16, 95% CI 0.10-0.25). The average rate of vancomycin resistance in Enterococcus isolates from haematology blood cultures was 4% compared with none for oncology. Surveillance of bacteraemia in haematology and oncology patients E. coli was the most common isolate of Gram-negative bacteraemia in both cancer groups (Table 1) , but with a higher incidence/1000 admissions in haematology patients (0.92, 95% CI 0.66-1.25) compared with oncology patients (0.50, 95% CI 0.38-0.64). Pseudomonas spp. were the second most common Gram-negative pathogens in haematology and demonstrated a 4-fold higher incidence of bacteraemia/1000 admissions compared with oncology patients (0.76, 95% CI 0.52-1.06 versus 0.19, 95% CI 0.12 -0.28) ( Table 1 ). Other Gram-negative bacteria, including Enterobacter/Citrobacter spp., Stenotrophomonas spp. and Klebsiella spp., also caused bacteraemia to various degrees ( Table 1) .
The rarer miscellaneous pathogens causing bacteraemia included anaerobes, atypical mycobacteria and actinomycetes, none of which differed significantly between patient groups (Table 1) . Fungi were a rare cause of bloodstream infections (Table 1) . There was one case of Cryptococcus neoformans fungaemia in a haematology patient presenting with pneumonia. The overall incidence of candidaemia was 0.04/1000 admissions (95% CI 0.02-0.09) for oncology and 0.28/1000 admissions (95% CI 0.14-0.48) for haematology patients. The candidaemia incidence/1000 admissions with non-Candida albicans was higher for haematology (0.18, 95% CI 0.08 -0.36) compared with oncology patients (0.03, 95% CI 0.01-0.07). In both groups combined the non-C. albicans infections were due to five Candida tropicalis isolates, three Candida glabrata isolates, two Candida parapsilosis isolates and one Candida krusei isolate. The mean rate of antimicrobial resistance to gentamicin, piperacillin/tazobactam, ceftazidime and meropenem was ,10% in both cancer groups, whereas resistance to ciprofloxacin was much higher (22%) in Gram-negative isolates of haematology patients compared with 5% in oncology patients (Figure 3) . However, the rate of ciprofloxacin use measured in DDDs of ciprofloxacin/10 admissions showed a high ciprofloxacin consumption in haematology patients compared with oncology patients (3.6 versus 1.5 DDDs/10 admissions, respectively) ( Figure 4) . Poisson regression of the count of Gram-negative isolates resistant to ciprofloxacin, year, specialty, DDDs/10 admissions and the count from the previous year was performed ( Table 2 ). It can be seen that there was a significant negative association with the number of Gram-negative bacilli (GNB) being resistant to ciprofloxacin from the previous year.
Although not quite significant, GNB resistance to ciprofloxacin in haematology patients was 2.8 times more likely to be resistant to ciprofloxacin (95% CI 0.97-8.07, P ¼ 0.058). Ciprofloxacin use was associated with a 1.4-fold increase in probability of resistance for every DDD/10 admissions extra, but this was also not statistically significant (95% CI 0.91 -2.46). The Pearson goodness of fit statistics gave x 2 ¼19.7, df ¼ 21, P ¼0.54, indicating that the model gave a good fit to the data. However, ciprofloxacin use and specialty was highly correlated (Figure 4) , raising the possibility of multicollinearity in a dataset with relatively few data points. In order to investigate this further we calculated the combined significance of the specialty and ciprofloxacin using the testparm command within STATA. 12 The calculated significance of the two variables together was high (x 2 ¼20.74, df ¼ 2, P, 0.0001), suggesting that multicollinearity was indeed an issue.
Discussion
Advances in early cancer diagnosis and new treatment approaches have improved the prognosis of cancer patients over the last decade in the UK. 13 Unfortunately, severe infections continue to be among the important complications contributing significantly to the morbidity and mortality of these patients. The annual incidence of severe sepsis in cancer patients has been estimated to be as high as 16.4 cases/1000 people, with an in-hospital mortality of 38%, despite comprehensive clinical practice guidelines for the management of febrile neutropenia and sepsis. 2,14 -16 Whilst one reason for this may be host-specific risk factors promoting severe sepsis, such as prolonged neutropenia, the presence of co-morbidities, vascular devices and advanced age, other important factors relate to the appropriate, Surveillance of bacteraemia in haematology and oncology patients timely prescribing of systemic antimicrobial agents and the susceptibility of the causative pathogen. 17 The surveillance of bloodstream infections and antimicrobial susceptibility therefore remains an important, integral part of the routine multidisciplinary provision of care in managing patients with cancer.
Our surveillance study has shown a fluctuating incidence of bacteraemia (including fungaemia) over the last 14 years, with an overall incidence of 5.5/1000 cancer patient admissions. Unsurprisingly, haematology patients had a 3-fold higher incidence of bacteraemia compared with oncology patients, which is probably due to the fact that those with leukaemia and other myelosuppressive disorders are known to have higher levels of immunosuppression, particularly neutropenia, and more frequent use of intravascular catheters. 18 Despite the discrepancies between the two cancer groups, we have seen a significant downward trend in haematology bacteraemias in general. Further surveillance will need to establish the longevity of this trend and whether this could be attributable to specific implemented interventions such as enhanced line care policy or introduction of the 'sepsis bundle', which includes the timely implementation of empirical antibiotics in sepsis patients. 19, 20 On analysis of the causative pathogens of bacteraemia, Grampositive organisms remain the most common pathogen group in both haematology and oncology bacteraemic patients in our study, confirming a stable trend over more than a decade. Similar ratios have been reported by others in a recent haematology study, with 57% of bloodstream infections being caused by Gram-positive and 38% by Gram-negative organisms. 21 The shift to more Gram-positive infections since the 1990s has been attributed to the increased use of invasive vascular devices such as Hickman lines and the introduction of fluoroquinolone prophylaxis, which has reduced Gram-negative bacteraemia but has led to an increase in fluoroquinolone-resistant Gram-positive infections such as viridians streptococci. 22, 23 The relatively high incidence of viridans streptococci observed in our haematology population (1.2/1000 admissions) reflects the fact that this group of patients typically suffers more commonly from associated risk factors, including severe mucositis and neutropenia, in contrast to solid tumour patients. 23 Nevertheless, compared with previous published data, our findings suggest that the incidence is now lower than described in the 1980s, which was reported to be 4.7/1000 admissions. 4 MRSA bloodstream infections also remain low in our cancer group (0.16/1000 admissions) compared with the incidences reported in the general hospital population from other European countries (0.3/1000 admissions in Italy). 24 Unfortunately, MRSA rates were not available from the literature to directly compare the rates in haematology and oncology patients from within the UK due to a difference in denominator or case definition. Nevertheless, the overall proportion of MSSA to MRSA bacteraemia in our study was comparable to that recently published for the general UK population, and much lower than that in other countries. 25 Severe immunosuppression, broad-spectrum antimicrobial agents and loss of mucosal integrity (e.g. mucositis) is also known to predispose patients to invasive fungal infections. Our study has shown an incidence of candidaemia of 0.04 and 0.3/1000 admissions for oncology and haematology, respectively, which is similar to incidences reported among the general hospital-based population, suggesting that candidaemia is not a particularly common infection in our cancer population. 26 More of a concern is the dominance of non-C. albicans isolates as they are often more resistant to fluconazole, which is a commonly used antifungal prophylactic agent for high-risk patients. Regular surveillance of the prevalent Candida species in cancer units is therefore recommended in order to guide appropriate choice of antifungal prophylaxis and treatment.
Whilst fungaemia remains rare in our haemo-oncology population, Gram-negative bacteraemia, particularly that due to Pseudomonas spp. (the second most common isolate in our haematology patients), poses a continuing threat. The relatively high percentage (7%) of Pseudomonas as a cause of bacteraemia episodes in our haematology patients shows an increase compared with previously published data from 1998 to 2000, reporting an average of 3%-4% in a similar patient population in Northern Ireland. 27 The increased trend has also been reported by others, emphasizing the ongoing need for adequate anti-pseudomonal cover during antibiotic treatment of febrile episodes in cancer patients. 21 The level of antibiotic resistance to first-line Gram-negative antibiotics, including extended-spectrum b-lactamases (ESBLs), was low (,10%) compared with some other European centres, which have recently reported a rate of 14% of multidrugresistant strains, with a high percentage (50%) of ESBL resitance. 28 A factor contributing to our low resistance rate may be the restriction of cephalosporins and carbapenems in the hospital; these agents are known to exert selective pressure on the organisms, leading to increased resistance. 29 The restricted antibiotic policy had been introduced as part of an attempt to control Clostridium difficile diarrhoea in combination with enhanced infection control practices.
More alarming is the high incidence of resistance to ciprofloxacin among the Gram-negative bacteraemia isolates in our haematology patients. Ciprofloxacin and other newer fluoroquinolones are frequently and routinely used for prophylaxis in highrisk neutropenic patients in many cancer and bone marrow transplant units. Our analysis suggests an association between ciprofloxacin consumption and resistance in Gram-negative bacteraemia isolates, though a larger study would be needed to better determine the exact relationship. Paradoxically, our Poisson regression model found a significant negative association between the number of ciprofloxacin-resistant GNB in one year and the corresponding number in the previous year. This is an unexpected finding, for which we are unable to offer a plausible explanation other than assuming that this may be a chance association.
The general association between ciprofloxacin use and resistance was observed as early as the first introduction of ciprofloxacin prophylaxis in the 1980s and has since been noted by others. 30 -32 Fluoroquinolones exert selective pressure on the gut microbial flora, leading to increased colonization by resistant bacteria. 31 It is tempting to suggest that centres with a high ciprofloxacin resistance will see a declining benefit of fluoroquinolones for the prevention of Gram-negative sepsis in cancer patients. However, to date there are insufficient data to suggest that the observed increase in fluoroquinolone resistance is directly associated with an increase in febrile episodes in neutropenic patients or infection-related mortality. International and national professional bodies therefore continue recommending fluoroquinolone prophylaxis in their guidelines for intermediate-and high-risk cancer patients. 13, 33 An alternative approach may be the discontinuation of fluoroquinolone as a prophylactic agent altogether, as suggested by some. 30 A less radical option is the rotation or cycling of antibiotics because fluoroquinolone resistance has been shown to be transient when ciprofloxacin prophylaxis is discontinued, leading to a decreased level of Gram-negatives resistant to this antibiotic. 31 Others have shown that a combination of ciprofloxacin with an oral non-absorbable antibiotic such as colistin has the beneficial effect of preventing the emergence of ciprofloxacin resistance whilst increasing the benefit of preventing infection. 34 In the meantime, regular resistance surveillance, good antimicrobial stewardship and infection control practices will remain crucial in combating antimicrobial resistance and devising effective antibiotic policies.
In summary, our longitudinal surveillance of bloodstream infections and antimicrobial resistance highlights the continued importance of Gram-negative bacteraemia, particularly that due to Pseudomonas spp., in the cancer population and raises concerns regarding increasing ciprofloxacin use and resistance.
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